Sumitomo Mitsui Trust Group Inc. Grows Position in Guardant Health, Inc. (NASDAQ:GH)

Sumitomo Mitsui Trust Group Inc. lifted its holdings in Guardant Health, Inc. (NASDAQ:GH) by 19.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,464,213 shares of the company’s stock after buying an additional 238,037 shares during the period. Sumitomo Mitsui Trust Group Inc. owned approximately 1.19% of Guardant Health worth $44,732,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of GH. China Universal Asset Management Co. Ltd. lifted its position in Guardant Health by 10.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,198 shares of the company’s stock worth $800,000 after buying an additional 2,537 shares in the last quarter. R Squared Ltd acquired a new stake in shares of Guardant Health in the 4th quarter worth $26,000. KBC Group NV raised its holdings in shares of Guardant Health by 63.6% during the 4th quarter. KBC Group NV now owns 5,658 shares of the company’s stock worth $173,000 after acquiring an additional 2,200 shares during the period. Wealthcare Advisory Partners LLC acquired a new position in shares of Guardant Health during the 4th quarter valued at about $252,000. Finally, Fiduciary Alliance LLC grew its holdings in shares of Guardant Health by 7.6% in the fourth quarter. Fiduciary Alliance LLC now owns 11,879 shares of the company’s stock valued at $363,000 after purchasing an additional 836 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Leerink Partners decreased their target price on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. The Goldman Sachs Group upped their price objective on Guardant Health from $36.00 to $49.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. Barclays initiated coverage on Guardant Health in a research note on Thursday, January 23rd. They set an “overweight” rating and a $60.00 target price for the company. Sanford C. Bernstein decreased their price target on Guardant Health from $40.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 30th. Finally, Guggenheim reissued a “buy” rating on shares of Guardant Health in a research report on Wednesday, January 22nd. Sixteen investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $42.63.

Insider Transactions at Guardant Health

In other news, Director Meghan V. Joyce sold 2,896 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total transaction of $86,590.40. Following the completion of the transaction, the director now directly owns 7,648 shares of the company’s stock, valued at approximately $228,675.20. The trade was a 27.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Musa Tariq sold 2,320 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $35.00, for a total transaction of $81,200.00. Following the completion of the sale, the director now directly owns 2,676 shares in the company, valued at approximately $93,660. This trade represents a 46.44 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,548 shares of company stock valued at $179,782. 5.50% of the stock is currently owned by company insiders.

Guardant Health Stock Down 0.2 %

Shares of GH opened at $44.40 on Tuesday. The company has a market cap of $5.49 billion, a P/E ratio of -10.47 and a beta of 1.32. Guardant Health, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $50.89. The firm’s 50 day moving average price is $38.30 and its 200 day moving average price is $30.74.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.